Difference between revisions of "He SZ, et al. Leuk. Lymphoma (2015) cited as Ref 556 in DOI: 10.1038/s41392-020-0110-5 (Q9819)"
Jump to navigation
Jump to search
(Created claim: Volume (P103): 56, #quickstatements; #temporary_batch_1590009084631) |
(Created claim: title (P93): A phase 1 study of the safety pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed refractory or high-risk acute myeloid leukemia, #quickstatements; #tempor...) |
||
| Property / title | |||
| + | A phase 1 study of the safety pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed refractory or high-risk acute myeloid leukemia (English) | ||
| Property / title: A phase 1 study of the safety pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed refractory or high-risk acute myeloid leukemia (English) / rank | |||
| + | Normal rank | ||
Revision as of 22:04, 20 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
He SZ, et al. Leuk. Lymphoma (2015) cited as Ref 556 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
He SZ
0 references
2015
0 references
Leuk. Lymphoma
0 references
56
0 references
A phase 1 study of the safety pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed refractory or high-risk acute myeloid leukemia (English)
0 references
